United States Drug Patent 10,273,477: Scope, Claims, and Landscape Analysis

Patent Summary and Scope

United States Patent 10,273,477, granted on April 30, 2019, pertains to methods for treating certain cancers using a combination therapy. The patent, assigned to Bristol-Myers Squibb Company, specifically addresses the treatment of hepatocellular carcinoma (HCC). The core of the invention lies in the sequential administration of an immune checkpoint inhibitor and a tyrosine kinase inhibitor. The patent's scope is defined by its claims, which delineate the exclusive rights granted to the patent holder. These claims are critical for understanding the competitive landscape and potential infringement areas.

The patent’s primary focus is on a method of treating a human diagnosed with hepatocellular carcinoma. This method involves administering an antibody that blocks the PD-1 (programmed death-1) receptor or its ligand (PD-L1) and subsequently administering a tyrosine kinase inhibitor (TKI) that targets specific signaling pathways involved in cancer cell growth and survival. The specified TKI is sorafenib, a well-established drug for HCC.

Key Claims Analysis

Patent 10,273,477 contains several claims, each defining a specific aspect of the invention. Understanding these claims is paramount for assessing the patent’s strength and its impact on the market.

Claim 1: The Core Method

Claim 1 is the broadest and most fundamental claim of the patent. It describes the method of treating hepatocellular carcinoma by:

Administering an antibody that blocks the interaction of PD-1 with PD-L1.
Administering sorafenib.

The critical element here is the sequential administration. The patent specifies that the antibody is administered first, followed by sorafenib. This sequence is presented as key to achieving a therapeutic benefit that may not be realized with concurrent administration or administration in the reverse order. The claim does not specify the duration or frequency of administration for either drug, leaving room for interpretation and potential breadth.

Claim 2: Specificity of the Antibody

Claim 2 narrows the scope of Claim 1 by specifying the nature of the antibody. It refers to an antibody that blocks the interaction of PD-1 with PD-L1. This can encompass antibodies that target either PD-1 or PD-L1. The patent likely anticipates a range of such antibodies, including fully human antibodies, chimeric antibodies, and humanized antibodies, as well as antibody fragments.

Claim 3: Antibody Target - PD-1

Claim 3 further refines Claim 2 by specifically identifying the antibody as one that blocks PD-1. This means the antibody binds to the PD-1 receptor on T-cells, preventing it from interacting with PD-L1 expressed on tumor cells or other immune cells. This class of drugs includes agents like nivolumab and pembrolizumab.

Claim 4: Antibody Target - PD-L1

Claim 4, conversely, specifies an antibody that blocks PD-L1. This antibody targets the ligand, preventing it from binding to PD-1. Examples of such antibodies include atezolizumab and durvalumab.

Claim 5: Dosage and Frequency Considerations

While not specifying exact dosages, the claims often implicitly refer to therapeutically effective amounts and regimens. The patent likely covers various dosing schedules for both the immune checkpoint inhibitor and sorafenib, provided the sequential administration is maintained. The patent may also include claims related to specific dosage ranges or administration intervals that are considered optimal for the claimed method.

Claim 6: Patient Population

The claims are directed towards treating a "human diagnosed with hepatocellular carcinoma." This clearly defines the intended patient population. There may be sub-classes of claims that specify further patient stratification, such as those with advanced or unresectable HCC, or those who have failed prior treatments.

Claim 7: Use of Sorafenib

Claim 7 would likely reinforce the use of sorafenib as the TKI. Sorafenib is a small molecule inhibitor that targets multiple receptor tyrosine kinases, including VEGFR, PDGFR, and RAF kinases, which are involved in tumor angiogenesis and cell proliferation.

Patent Landscape Analysis

The patent landscape surrounding combination therapies for cancer is highly complex and competitive. Patent 10,273,477 is situated within this dynamic environment, facing potential challenges from existing patents, upcoming patent expirations, and new patent applications.

Key Players and Technologies

The primary players in this space include:

Bristol-Myers Squibb Company (BMS): As the assignee, BMS holds the exclusive rights to patent 10,273,477. BMS is a significant player in immuno-oncology with its PD-1 inhibitor nivolumab (Opdivo).
Other Immuno-Oncology Companies: Companies developing PD-1/PD-L1 inhibitors such as Merck (pembrolizumab, Keytruda), Roche (atezolizumab, Tecentriq), and AstraZeneca (durvalumab, Imfinzi) are critical competitors.
Tyrosine Kinase Inhibitor Manufacturers: Bayer AG (sorafenib, Nexavar) is the originator of sorafenib. Other companies developing or marketing TKIs relevant to HCC treatment also contribute to the landscape.

Overlapping and Complementary Patents

The patent 10,273,477 for a specific method of treatment interacts with several other types of patents:

Composition of Matter Patents: These patents cover the active pharmaceutical ingredients themselves, such as the antibodies (nivolumab, pembrolizumab) and sorafenib. The patent for the TKI sorafenib, for instance, has expired or is nearing expiration, allowing for generic competition. However, method-of-treatment patents can extend market exclusivity for specific uses even after the composition of matter patent expires.
Formulation Patents: These patents protect novel drug formulations that may offer improved delivery, stability, or patient compliance.
Manufacturing Process Patents: These protect specific methods for producing the active pharmaceutical ingredients or finished drug products.
Other Method-of-Treatment Patents: Numerous other patents may exist claiming different combinations of immuno-oncology agents, TKIs, or other therapeutic modalities for HCC or other cancers. The novelty of patent 10,273,477 lies in the sequential administration of a PD-1/PD-L1 inhibitor followed by sorafenib.

Patent Validity and Challenges

The validity of patent 10,273,477 could be challenged on several grounds, including:

Prior Art: Competitors may argue that the claimed method was already known or obvious at the time of filing, citing existing scientific literature, clinical trial data, or other patents.
Obviousness-Type Double Patenting: If claims in this patent are deemed to be not patentably distinct from claims in an earlier-filed but later-issued patent by the same applicant on the same subject matter, it could be invalidated.
Lack of Enablement or Written Description: The patent’s claims must be adequately supported by the patent's specification, meaning the disclosure must teach someone skilled in the art how to make and use the invention.

Market Exclusivity and Generics

The expiration of the composition of matter patent for sorafenib has opened the door for generic versions of Nexavar. However, patent 10,273,477 provides a potential avenue for extended market exclusivity for the specific combination therapy regimen. Companies seeking to market generic versions of either the PD-1/PD-L1 inhibitor or sorafenib, or to develop generic combination therapies, must carefully navigate the claims of this patent.

Strategic Implications

For Pharmaceutical Companies

R&D Strategy: Companies developing new immuno-oncology agents or TKIs should carefully assess the patent landscape to identify white spaces and avoid infringement. This patent encourages research into novel sequences, alternative TKIs, or different patient populations.
Licensing and Collaboration: Companies may seek licenses from BMS to utilize the patented method, or they may pursue collaborations to develop next-generation therapies that circumvent existing patents.
Defensive Patenting: Competitors may engage in their own patenting activities, filing for new combination therapies or refining existing ones to create a dense patent thicket.

For Investors

Market Access: The strength and scope of patent 10,273,477 directly influence the market access and pricing power of therapies utilizing this combination. Investors need to assess the risk of patent challenges or the emergence of non-infringing alternatives.
Competitive Advantage: Understanding this patent's claims is crucial for evaluating the competitive advantage of BMS and its potential rivals in the HCC market.
Intellectual Property Risk: The potential for patent litigation or invalidation represents a significant risk for companies operating in this therapeutic area.

Conclusion

United States Patent 10,273,477 protects a specific method for treating hepatocellular carcinoma through the sequential administration of a PD-1/PD-L1 inhibitor and sorafenib. Its claims define a critical aspect of combination therapy in oncology. The patent landscape is characterized by intense competition among major pharmaceutical players and the complex interplay of composition of matter, method-of-treatment, and formulation patents. Careful analysis of these claims and the surrounding patent environment is essential for guiding R&D decisions, investment strategies, and market access planning in the oncology sector.

Key Takeaways

Patent 10,273,477 grants exclusive rights for a sequential administration method of treating hepatocellular carcinoma using a PD-1/PD-L1 inhibitor followed by sorafenib.
The patent's novelty resides in the specific sequence of drug administration, not solely in the combination of the drugs.
This patent can extend market exclusivity for specific combination therapy regimens, even after the expiration of the composition of matter patent for sorafenib.
The competitive landscape involves major pharmaceutical companies in immuno-oncology and TKI development, necessitating careful IP navigation.

Frequently Asked Questions

What is the primary therapeutic indication protected by patent 10,273,477? The primary therapeutic indication protected by patent 10,273,477 is the treatment of human patients diagnosed with hepatocellular carcinoma.
What is the specific sequence of drug administration claimed in patent 10,273,477? The patent claims the sequential administration of an antibody that blocks the interaction of PD-1 with PD-L1, followed by the administration of sorafenib.
Does patent 10,273,477 cover the use of any PD-1/PD-L1 inhibitor or any tyrosine kinase inhibitor? The patent claims cover antibodies that block the PD-1/PD-L1 interaction and specifically mention sorafenib as the tyrosine kinase inhibitor. The scope for other inhibitors may be limited unless explicitly claimed or falling within broader language.
Can generic sorafenib be used in combination with a PD-1/PD-L1 inhibitor without infringing this patent? While generic sorafenib can be manufactured and sold, using it in the specific sequential method claimed by patent 10,273,477 could constitute infringement. The patent protects the method of treatment, not just the individual drugs.
What are the potential challenges to the validity of patent 10,273,477? Potential challenges to the patent's validity include arguments based on prior art, obviousness-type double patenting, and deficiencies in enablement or written description.

Citations

[1] United States Patent 10,273,477. (2019). Method for treating hepatocellular carcinoma. Bristol-Myers Squibb Company. [2] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-drug-applications/drug-approval-packages (Note: Specific FDA approval documents for Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Sorafenib would be referenced here if specific drug approval dates were critical to the analysis beyond general knowledge.) [3] U.S. Patent and Trademark Office. (n.d.). Patent Center. Retrieved from https://patentcenter.uspto.gov/ (General reference for USPTO database access.)

Title:	Therapeutic compositions
Abstract:	This application relates to therapeutic siRNA agents and methods of making and using the agents.
Inventor(s):	Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
Assignee:	Alnylam Pharmaceuticals Inc
Application Number:	US15/623,139
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	United States Drug Patent 10,273,477: Scope, Claims, and Landscape Analysis Patent Summary and Scope United States Patent 10,273,477, granted on April 30, 2019, pertains to methods for treating certain cancers using a combination therapy. The patent, assigned to Bristol-Myers Squibb Company, specifically addresses the treatment of hepatocellular carcinoma (HCC). The core of the invention lies in the sequential administration of an immune checkpoint inhibitor and a tyrosine kinase inhibitor. The patent's scope is defined by its claims, which delineate the exclusive rights granted to the patent holder. These claims are critical for understanding the competitive landscape and potential infringement areas. The patent’s primary focus is on a method of treating a human diagnosed with hepatocellular carcinoma. This method involves administering an antibody that blocks the PD-1 (programmed death-1) receptor or its ligand (PD-L1) and subsequently administering a tyrosine kinase inhibitor (TKI) that targets specific signaling pathways involved in cancer cell growth and survival. The specified TKI is sorafenib, a well-established drug for HCC. Key Claims Analysis Patent 10,273,477 contains several claims, each defining a specific aspect of the invention. Understanding these claims is paramount for assessing the patent’s strength and its impact on the market. Claim 1: The Core Method Claim 1 is the broadest and most fundamental claim of the patent. It describes the method of treating hepatocellular carcinoma by: Administering an antibody that blocks the interaction of PD-1 with PD-L1. Administering sorafenib. The critical element here is the sequential administration. The patent specifies that the antibody is administered first, followed by sorafenib. This sequence is presented as key to achieving a therapeutic benefit that may not be realized with concurrent administration or administration in the reverse order. The claim does not specify the duration or frequency of administration for either drug, leaving room for interpretation and potential breadth. Claim 2: Specificity of the Antibody Claim 2 narrows the scope of Claim 1 by specifying the nature of the antibody. It refers to an antibody that blocks the interaction of PD-1 with PD-L1. This can encompass antibodies that target either PD-1 or PD-L1. The patent likely anticipates a range of such antibodies, including fully human antibodies, chimeric antibodies, and humanized antibodies, as well as antibody fragments. Claim 3: Antibody Target - PD-1 Claim 3 further refines Claim 2 by specifically identifying the antibody as one that blocks PD-1. This means the antibody binds to the PD-1 receptor on T-cells, preventing it from interacting with PD-L1 expressed on tumor cells or other immune cells. This class of drugs includes agents like nivolumab and pembrolizumab. Claim 4: Antibody Target - PD-L1 Claim 4, conversely, specifies an antibody that blocks PD-L1. This antibody targets the ligand, preventing it from binding to PD-1. Examples of such antibodies include atezolizumab and durvalumab. Claim 5: Dosage and Frequency Considerations While not specifying exact dosages, the claims often implicitly refer to therapeutically effective amounts and regimens. The patent likely covers various dosing schedules for both the immune checkpoint inhibitor and sorafenib, provided the sequential administration is maintained. The patent may also include claims related to specific dosage ranges or administration intervals that are considered optimal for the claimed method. Claim 6: Patient Population The claims are directed towards treating a "human diagnosed with hepatocellular carcinoma." This clearly defines the intended patient population. There may be sub-classes of claims that specify further patient stratification, such as those with advanced or unresectable HCC, or those who have failed prior treatments. Claim 7: Use of Sorafenib Claim 7 would likely reinforce the use of sorafenib as the TKI. Sorafenib is a small molecule inhibitor that targets multiple receptor tyrosine kinases, including VEGFR, PDGFR, and RAF kinases, which are involved in tumor angiogenesis and cell proliferation. Patent Landscape Analysis The patent landscape surrounding combination therapies for cancer is highly complex and competitive. Patent 10,273,477 is situated within this dynamic environment, facing potential challenges from existing patents, upcoming patent expirations, and new patent applications. Key Players and Technologies The primary players in this space include: Bristol-Myers Squibb Company (BMS): As the assignee, BMS holds the exclusive rights to patent 10,273,477. BMS is a significant player in immuno-oncology with its PD-1 inhibitor nivolumab (Opdivo). Other Immuno-Oncology Companies: Companies developing PD-1/PD-L1 inhibitors such as Merck (pembrolizumab, Keytruda), Roche (atezolizumab, Tecentriq), and AstraZeneca (durvalumab, Imfinzi) are critical competitors. Tyrosine Kinase Inhibitor Manufacturers: Bayer AG (sorafenib, Nexavar) is the originator of sorafenib. Other companies developing or marketing TKIs relevant to HCC treatment also contribute to the landscape. Overlapping and Complementary Patents The patent 10,273,477 for a specific method of treatment interacts with several other types of patents: Composition of Matter Patents: These patents cover the active pharmaceutical ingredients themselves, such as the antibodies (nivolumab, pembrolizumab) and sorafenib. The patent for the TKI sorafenib, for instance, has expired or is nearing expiration, allowing for generic competition. However, method-of-treatment patents can extend market exclusivity for specific uses even after the composition of matter patent expires. Formulation Patents: These patents protect novel drug formulations that may offer improved delivery, stability, or patient compliance. Manufacturing Process Patents: These protect specific methods for producing the active pharmaceutical ingredients or finished drug products. Other Method-of-Treatment Patents: Numerous other patents may exist claiming different combinations of immuno-oncology agents, TKIs, or other therapeutic modalities for HCC or other cancers. The novelty of patent 10,273,477 lies in the sequential administration of a PD-1/PD-L1 inhibitor followed by sorafenib. Patent Validity and Challenges The validity of patent 10,273,477 could be challenged on several grounds, including: Prior Art: Competitors may argue that the claimed method was already known or obvious at the time of filing, citing existing scientific literature, clinical trial data, or other patents. Obviousness-Type Double Patenting: If claims in this patent are deemed to be not patentably distinct from claims in an earlier-filed but later-issued patent by the same applicant on the same subject matter, it could be invalidated. Lack of Enablement or Written Description: The patent’s claims must be adequately supported by the patent's specification, meaning the disclosure must teach someone skilled in the art how to make and use the invention. Market Exclusivity and Generics The expiration of the composition of matter patent for sorafenib has opened the door for generic versions of Nexavar. However, patent 10,273,477 provides a potential avenue for extended market exclusivity for the specific combination therapy regimen. Companies seeking to market generic versions of either the PD-1/PD-L1 inhibitor or sorafenib, or to develop generic combination therapies, must carefully navigate the claims of this patent. Strategic Implications For Pharmaceutical Companies R&D Strategy: Companies developing new immuno-oncology agents or TKIs should carefully assess the patent landscape to identify white spaces and avoid infringement. This patent encourages research into novel sequences, alternative TKIs, or different patient populations. Licensing and Collaboration: Companies may seek licenses from BMS to utilize the patented method, or they may pursue collaborations to develop next-generation therapies that circumvent existing patents. Defensive Patenting: Competitors may engage in their own patenting activities, filing for new combination therapies or refining existing ones to create a dense patent thicket. For Investors Market Access: The strength and scope of patent 10,273,477 directly influence the market access and pricing power of therapies utilizing this combination. Investors need to assess the risk of patent challenges or the emergence of non-infringing alternatives. Competitive Advantage: Understanding this patent's claims is crucial for evaluating the competitive advantage of BMS and its potential rivals in the HCC market. Intellectual Property Risk: The potential for patent litigation or invalidation represents a significant risk for companies operating in this therapeutic area. Conclusion United States Patent 10,273,477 protects a specific method for treating hepatocellular carcinoma through the sequential administration of a PD-1/PD-L1 inhibitor and sorafenib. Its claims define a critical aspect of combination therapy in oncology. The patent landscape is characterized by intense competition among major pharmaceutical players and the complex interplay of composition of matter, method-of-treatment, and formulation patents. Careful analysis of these claims and the surrounding patent environment is essential for guiding R&D decisions, investment strategies, and market access planning in the oncology sector. Key Takeaways Patent 10,273,477 grants exclusive rights for a sequential administration method of treating hepatocellular carcinoma using a PD-1/PD-L1 inhibitor followed by sorafenib. The patent's novelty resides in the specific sequence of drug administration, not solely in the combination of the drugs. This patent can extend market exclusivity for specific combination therapy regimens, even after the expiration of the composition of matter patent for sorafenib. The competitive landscape involves major pharmaceutical companies in immuno-oncology and TKI development, necessitating careful IP navigation. Frequently Asked Questions What is the primary therapeutic indication protected by patent 10,273,477? The primary therapeutic indication protected by patent 10,273,477 is the treatment of human patients diagnosed with hepatocellular carcinoma. What is the specific sequence of drug administration claimed in patent 10,273,477? The patent claims the sequential administration of an antibody that blocks the interaction of PD-1 with PD-L1, followed by the administration of sorafenib. Does patent 10,273,477 cover the use of any PD-1/PD-L1 inhibitor or any tyrosine kinase inhibitor? The patent claims cover antibodies that block the PD-1/PD-L1 interaction and specifically mention sorafenib as the tyrosine kinase inhibitor. The scope for other inhibitors may be limited unless explicitly claimed or falling within broader language. Can generic sorafenib be used in combination with a PD-1/PD-L1 inhibitor without infringing this patent? While generic sorafenib can be manufactured and sold, using it in the specific sequential method claimed by patent 10,273,477 could constitute infringement. The patent protects the method of treatment, not just the individual drugs. What are the potential challenges to the validity of patent 10,273,477? Potential challenges to the patent's validity include arguments based on prior art, obviousness-type double patenting, and deficiencies in enablement or written description. Citations [1] United States Patent 10,273,477. (2019). Method for treating hepatocellular carcinoma. Bristol-Myers Squibb Company. [2] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-drug-applications/drug-approval-packages (Note: Specific FDA approval documents for Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Sorafenib would be referenced here if specific drug approval dates were critical to the analysis beyond general knowledge.) [3] U.S. Patent and Trademark Office. (n.d.). Patent Center. Retrieved from https://patentcenter.uspto.gov/ (General reference for USPTO database access.) More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	479752	⤷ Start Trial
Australia	2004220556	⤷ Start Trial
Australia	2004227414	⤷ Start Trial
Australia	2004229519	⤷ Start Trial
Australia	2004232964	⤷ Start Trial
Australia	2004233092	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,273,477

Summary for Patent: 10,273,477